Search clinical trials for: pharmacokinetics, hepatic impairment

Total 10362 results

Biotie Therapies Inc.
Acorda Therapeutics

Terminated

Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Tozadenant

Hepatic Impairment

United States
Novo Nordisk A/S

Completed

Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function

Diabetes Mellitus, Type 2 | Diabetes | Hepatic Impaired

Poland, Slovakia
FUJIFILM Toyama Chemical Co., Ltd.
Celerion

Completed

PK Study of T-817 in Subjects With Hepatic Impairment

Healthy | Hepatic Impairment

United States
Celgene

Completed

NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma

Melanoma | Lymphoma | Multiple Myeloma | Pancreatic Cancer | Non-Small Cell Lung Cancer

Australia
GlaxoSmithKline

Completed

Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or Severe Hepatic Impairment

Purpura, Thrombocytopaenic, Idiopathic

United States, Australia, New Zealand
GlaxoSmithKline

Completed

Investigating The Pharmacokinetics Of An Inhaled Dose Of A New Corticosteroid In Patients With Impaired Liver Function

Asthma
Takeda

Completed

Phase I Open-label Study to Evaluate Pharmacokinetics of TAK-272 in Participants With Renal or Hepatic Impairment

Renal Impairment | Hepatic Impairment

Japan
Enanta Pharmaceuticals, Inc

Completed

A Study of EDP-305 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers

NASH

United States, Czechia, Slovakia
Janssen Research & Development, LLC

Withdrawn

A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Odalasvir and AL-335 Alone and in Combination With Simeprevir in Participants With Moderately Impaired Hepatic Function

Hepatic Impairment
Nektar Therapeutics

Completed

A Study in Cancer Patients With Hepatic Impairment to Evaluate the Pharmacokinetics and Safety of NKTR-102 (Etirinotecan Pegol)

Advanced or Metastatic Solid Tumors in Patients With Hepatic Impairment

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Single-dose Pharmacokinetics of BMS-626529, Administered as BMS-663068, in Subjects With Hepatic Impairment Compared to Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
GlaxoSmithKline

Completed

Observational Study Evaluating The Processing Or Breakdown Of GW679769 In Subjects With Hepatic Impairment

Vomiting

United States
GlaxoSmithKline

Completed

A Study To Compare The Effects Of The Infusion Of A Sepsis Drug Between Healthy Adults And Adults With Damaged Livers

Sepsis

Slovakia
GlaxoSmithKline

Completed

A Study Of GW406381 In Volunteers With Moderate Hepatic Impairment

Pain

Hungary
PTC Therapeutics

Completed

A Single Dose Evaluation of the Effects of Moderate Hepatic Impairment on Deflazacort Pharmacokinetics

Hepatic Impairment

United States
Bayer

Completed

Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1002670 (Vilaprisan)

Leiomyoma

Germany
GlaxoSmithKline

Completed

Study to Evaluate Darapladib in Moderately Hepatically Impaired Subjects

Atherosclerosis

United States
GlaxoSmithKline

Completed

A Study to Assess the Effects of GSK573719/VI Combination and GSK573719 Monotherapy in Subjects With Moderate Hepatic Impairment and Matched Healthy Volunteers

Pulmonary Disease, Chronic Obstructive

Hungary, Slovakia
GlaxoSmithKline

Completed

A Study to Assess the Effects of Fluticasone Furoate and GW642444M Combination in Healthy Subjects and in Subjects With Mild, Moderate or Severe Hepatic Impairment.

Asthma

Czechia, Slovakia
GlaxoSmithKline

Completed

Study to Evaluate the Pharmacokinetics and Safety of GSK2336805 in Subjects With Hepatic Impairment and Healthy Matched Control Subjects

Hepatitis C

United States
Eisai Inc.

Completed

A Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy Subjects

Early Alzheimer's Disease

United States
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Safety and Pharmacokinetics/Pharmacodynamics of SHR3824 in Patients With Hepatic Impairment

Hepatic Impairment

China
Janssen Research & Development, LLC

Completed

A Study to Assess the Effects of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine

Hepatic Impairment | Normal Hepatic Function

United States
Amgen

Completed

Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment

Hepatic Impairment | Solid Tumors | Hematologic Malignancies

United Kingdom, Netherlands, United States, France
Genzyme, a Sanofi Company

Completed

A Study of the Effects of Hepatic Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate

Gaucher Disease

United States
Bristol-Myers Squibb

Withdrawn

A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants

Hepatic Impairment

United States
Horizon Pharma Ireland, Ltd., Dublin Ireland
Ucyclyd Pharma, Inc.

Completed

A Study of Glyceryl Tri-(4-phenylbutyrate) Administered Orally as a Single Dose, and Twice Daily for Seven Consecutive Days to Subjects With Hepatic Impairment With Cirrhosis and to a Control Group

Hepatic Encephalopathy | Urea Cycle Disorders

Ukraine
Lexicon Pharmaceuticals

Completed

PK Study of Sotagliflozin in Subjects With Hepatic Impairment

Healthy | Hepatic Impairment

United States
Hoffmann-La Roche

Completed

A Study on The Effect of Hepatic Impairment on The Pharmacokinetics of RO4917838

Healthy Volunteer

France, Russian Federation
Hoffmann-La Roche

Completed

A Safety And Pharmacokinetic Study of Setrobuvir Alone and In Combination With Ritonavir-Boosted Danoprevir in Subjects With Mild Hepatic Impairment Compared to Healthy Controls

Healthy Volunteer

Poland, Hungary
Hoffmann-La Roche

Completed

A Study of Danoprevir in Healthy Volunteers And Patients With Hepatic Impairment

Healthy Volunteer

Slovakia, United States, Czech Republic
Indivior Inc.

Completed

Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects

Hepatic Impairment | Hepatic Failure | Chronic Hepatitis C Infection With Hepatic Coma

United States
AstraZeneca

Completed

Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal or Impaired Kidney Function

Solid Tumours

Belgium, France, Netherlands, United Kingdom, Denmark
Hoffmann-La Roche

Terminated

A Study of the Pharmacokinetics/Pharmacodynamics of GK Activator (2) in Type 2 Diabetes Patients With Hepatic Impairment.

Diabetes Mellitus, Type 2

Germany, Slovakia
Hackensack Meridian Health

Completed

Pediatric Head Lice Study Product Comparison

Head Lice

United States
AstraZeneca

Completed

To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Patients With Hepatic Impairment and Healthy Subjects

Solid Tumors

United States
Trius Therapeutics LLC

Completed

A PK and Safety Study in Subjects With Hepatic Impairment

Hepatic Impairment

United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Pharmacokinetics of JNJ-38518168 in Patients With Mild and Moderate Hepatic Impairment Compared With Patients With Normal Hepatic Function

Hepatic Impairment

United States
Sanofi

Completed

Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy (TAO)

Acute Coronary Syndrome

Austria, Korea, Republic of, Brazil, Belarus, India, Latvia, Belgium, Canada, Israel, Portugal, Germany, United States, Argentina, Australia, Bulgaria, Chile, Colombia, Croatia, Czech Republic, Egypt, Estonia, France, Greece, Hong Kong, Hungar... and more
Debiopharm International SA

Completed

Evaluate the Pharmacokinetics, Safety, and Tolerability of Alisporivir in Subjects With Hepatic Impairment Compared to Healthy Subjects

Hepatic Insufficiency

United States
Conatus Pharmaceuticals Inc.

Completed

PK and PD Study of IDN-6556 in Subjects With Hepatic Impairment and Matched Healthy Volunteers

Liver Diseases | Digestive System Diseases | Hepatic Impairment

United States
Alkermes, Inc.

Completed

Pharmacokinetics and Safety of ALKS 5461 in Healthy Subjects and Subjects With Hepatic Impairment and Normal Hepatic Function

Hepatic Impairment

United States
Boehringer Ingelheim

Completed

Nintedanib in Volunteers With Hepatic Impairment Compared With Healthy Volunteers

Hepatic Insufficiency

Germany
Takeda

Completed

Pharmacokinetics, Safety and Tolerability of Vortioxetine in Normal Hepatic Function or Severe Hepatic Impairment

Severe Hepatic Impairment

United States
Hoffmann-La Roche

Completed

A Study of The Effect of Hepatic Impairment on The Pharmacokinetics of Aleglitazar

Healthy Volunteer

United States
Boehringer Ingelheim

Completed

BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3

Hepatitis C, Chronic

United States, Germany, Spain, United Kingdom
Wockhardt

Completed

Pharmacokinetics of WCK 2349 In Patients With Hepatic Impairment

Hepatic Impairment

United States
MDVI, LLC

Completed

Pharmacokinetics of Favipiravir in Volunteers With Hepatic Impairment

Healthy | Hepatic Impairment

United States
AbbVie

Completed

Pharmacokinetics and Safety of ABT-493 and/or ABT-530 in Subjects With Normal and Impaired Hepatic Function

Hepatic Impairment

United States, New Zealand
Bristol-Myers Squibb

Completed

Single-Dose Pharmacokinetics of BMS-790052 in Participants With Hepatic Impairment

Hepatic Insufficiency

United States

3

Subscribe